Literature DB >> 18660857

Weighing the risks: prostate cancer versus cardiovascular disease.

Danil V Makarov1, Alan W Partin.   

Abstract

Entities:  

Year:  2008        PMID： 18660857      PMCID： PMC2483320     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  5 in total

Review 1.  Androgen deprivation therapy for prostate cancer.

Authors:  Nima Sharifi; James L Gulley; William L Dahut
Journal:  JAMA       Date:  2005-07-13       Impact factor: 56.272

2.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

Authors:  Anthony V D'Amico; Judith Manola; Marian Loffredo; Andrew A Renshaw; Alyssa DellaCroce; Philip W Kantoff
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

3.  Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Authors:  Henry K Tsai; Anthony V D'Amico; Natalia Sadetsky; Ming-Hui Chen; Peter R Carroll
Journal:  J Natl Cancer Inst       Date:  2007-10-09       Impact factor: 13.506

4.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Andrew A Renshaw; Marian Loffredo; Philip W Kantoff
Journal:  JAMA       Date:  2008-01-23       Impact factor: 56.272

Review 5.  The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Mark S Litwin; Deborah P Lubeck; Shilpa S Mehta; James M Henning; Peter R Carroll
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.